doxazosin has been researched along with Hypertrophy, Left Ventricular in 14 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "Aim of the study was to evaluate the effects of a 6 month treatment with doxazosin on blood pressure profile, left ventricular morphology and function and microalbuminuria in non diabetics patients with mild to moderate essential hypertension." | 9.08 | [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension]. ( Bignotti, M; Lamponi, M, 1996) |
| " The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy." | 7.74 | Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007) |
| "Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 5.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "Aim of the study was to evaluate the effects of a 6 month treatment with doxazosin on blood pressure profile, left ventricular morphology and function and microalbuminuria in non diabetics patients with mild to moderate essential hypertension." | 5.08 | [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension]. ( Bignotti, M; Lamponi, M, 1996) |
| " The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy." | 3.74 | Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007) |
| " To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO)." | 3.73 | Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. ( Busca, G; Cesana, F; Clari, F; Ferrari, AU; Ferrero, I; Gatti, C; Janetti, MB; Mancia, G; Palladini, G; Perlini, S; Tozzi, R; Vezzoli, M, 2006) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| "CARDIOVASCULAR RISK OF LEFT VENTRICULAR HYPERTROPHY: Because of the rhythmic, mechanical and ischemic risk related to it, the left ventricular hypertrophy (LVH) is considered to be a major independent risk factor for cardiovascular disease which should be screened for and treated early." | 2.70 | [Management of hypertensive patients with left ventricular hypertrophy]. ( Ambrosioni, E, 2002) |
| "Established left ventricular hypertrophy (LVH) showed a significant alteration in the cardiac protein profile compared with normal heart." | 1.33 | Comparison of the protein profile of established and regressed hypertension-induced left ventricular hypertrophy. ( Barderas, MG; Duran, MC; Egido, J; Gallego-Delgado, J; Lazaro, A; Osende, JI; Vivanco, F, 2006) |
| "Doxazosin treatment reduced the formation of Bax-Bcl-2 complexes in the left ventricle of SHRs, and this was accompanied by a decrease in the levels of 85kDa PARP and a reduction in apoptotic left ventricular cells." | 1.31 | Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats. ( Aceituno, E; Ayala, R; Casado, S; Castilla, C; Farré, J; Fortes, J; García-Durán, M; González-Fernández, F; López-Farré, A; Rico, L; Rodríguez-Feo, JA, 2000) |
| "Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 1.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 11 (78.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, K | 1 |
| Oparil, S | 1 |
| Davis, BR | 1 |
| Tereshchenko, LG | 1 |
| Matsui, Y | 1 |
| Eguchi, K | 1 |
| Shibasaki, S | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Pickering, TG | 1 |
| Shimada, K | 1 |
| Kario, K | 1 |
| Barrios, V | 2 |
| Escobar, C | 2 |
| Tomás, JP | 2 |
| Calderon, A | 2 |
| Echarri, R | 2 |
| Gallego-Delgado, J | 2 |
| Connolly, SB | 1 |
| Lázaro, A | 2 |
| Sadlier, D | 1 |
| Kieran, NE | 1 |
| Sugrue, DD | 1 |
| Doran, P | 1 |
| Brady, HR | 1 |
| Osende, J | 1 |
| Egido, J | 2 |
| Ambrosioni, E | 1 |
| Pulcrano, M | 1 |
| Palmieri, EA | 1 |
| Pagano, L | 1 |
| Tauchmanova, L | 1 |
| Rossi, A | 1 |
| Fazio, S | 1 |
| Lombardi, G | 1 |
| Biondi, B | 1 |
| Osende, JI | 1 |
| Barderas, MG | 1 |
| Duran, MC | 1 |
| Vivanco, F | 1 |
| Perlini, S | 1 |
| Ferrero, I | 1 |
| Palladini, G | 1 |
| Tozzi, R | 1 |
| Gatti, C | 1 |
| Vezzoli, M | 1 |
| Cesana, F | 1 |
| Janetti, MB | 1 |
| Clari, F | 1 |
| Busca, G | 1 |
| Mancia, G | 1 |
| Ferrari, AU | 1 |
| Ikeda, T | 1 |
| Gomi, T | 1 |
| Shibuya, Y | 1 |
| Shinozaki, S | 1 |
| Suzuki, Y | 1 |
| Matsuda, N | 1 |
| Pool, JL | 1 |
| Bignotti, M | 1 |
| Lamponi, M | 1 |
| Rodríguez-Feo, JA | 1 |
| Fortes, J | 1 |
| Aceituno, E | 1 |
| Farré, J | 1 |
| Ayala, R | 1 |
| Castilla, C | 1 |
| Rico, L | 1 |
| González-Fernández, F | 1 |
| García-Durán, M | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Varagic, J | 1 |
| Susic, D | 1 |
| Frohlich, ED | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for doxazosin and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Effect of doxazosin on the left ventricular structure and function in morning hypertensive patients: the Japan Morning Surge 1 study.
Topics: Aged; Antihypertensive Agents; Circadian Rhythm; Doxazosin; Echocardiography; Female; Humans; Hypert | 2008 |
[Management of hypertensive patients with left ventricular hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2002 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
[Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension].
Topics: Albuminuria; Antihypertensive Agents; Doxazosin; Echocardiography; Female; Heart; Humans; Hypertensi | 1996 |
9 other studies available for doxazosin and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Doxazosin and heart failure: to be or not to be.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricul | 2009 |
Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies.
Topics: Animals; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Gene Expression; Gene Expres | 2009 |
Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraga
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Atenolol; Blood Pr | 2004 |
Comparison of the protein profile of established and regressed hypertension-induced left ventricular hypertrophy.
Topics: Amino Acid Sequence; Animals; Antihypertensive Agents; Blood Pressure; Doxazosin; Electrophoresis, G | 2006 |
Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Abdominal; Blood Pressure | 2006 |
Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Bloo | 2007 |
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
Topics: Coronary Disease; Doxazosin; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance | 1994 |
Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Pressure; Caspase 3; Caspases; Doxazosin; Hear | 2000 |
Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2001 |